Advancing Dendritic Cell Immunotherapy for Glioblastoma: Insights from Diakonos Oncology’s Jay Hartenbach

In this episode, Vera spoke with Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology, a company developing cancer immunotherapies to address the critical and unmet medical need of late-stage and aggressive cancers like glioblastoma.

Jay is a passionate advocate for wellness and innovative healthcare, bringing a unique blend of scientific knowledge, entrepreneurial enthusiasm and business strategy expertise to the Life Sciences industry.

He concurrently serves as the COO of another cancer immunotherapy company, Immunocine. Before moving to biotech, Jay co-founded wellness company Medterra, where he continues to shape the company’s strategic direction as Chairman of the Board. Jay also co-founded Perland Pharmaceuticals, an early-stage biotech company actively developing therapies for arthritis conditions.

Jay has a Masters in Engineering Management from Duke University and a Bachelor of Science in Biomedical Engineering from the University of Miami.

Tune into the episode to hear how Jay is helping drive new frontiers in cancer immunotherapy at Diakonos Oncology through scientific innovation and strategic leadership.

For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/

Follow Us on Social Media

Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured